A Phase 1, Open-label, Single-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
Latest Information Update: 21 Oct 2025
At a glance
- Drugs Miricorilant (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
Most Recent Events
- 30 Mar 2025 Status changed from recruiting to completed.
- 02 May 2024 Planned End Date changed from 31 Mar 2024 to 31 Dec 2024.
- 02 May 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Dec 2024.